跳至主要内容
临床试验/NCT00535548
NCT00535548Unknown1 期

Effect of Hematopoietic Stem Cells in Chronic Wounds Using a Pressure Sore Model: A Pilot Study on Feasibility, Safety and Potential Effects

University Hospital, Basel, Switzerland2 个研究点 分布在 1 个国家开始时间: 2007年1月1日最近更新:
适应症

试验速览

阶段
1 期
发起方
试验地点
2
主要终点
feasibility, safety, efficacy

研究概览

简要总结

Aim of the study:

Evaluation of feasibility, safety and potential effects of stem cells on chronic wounds using a pressure sore model.

Clinical relevance:

  • Accelerated healing of uncomplicated wounds
  • Enhanced healing of complicated (chronic, non-healing) wounds

Study design:

  • Prospective controlled phase I/II study
  • Cohort of 5 patients in pilot study, then reevaluation

Patients:

- Para- and tetraplegic patients with sacral pressure sores grade III-IVA according to the classification of Daniel and Seiler

Methods:

1. First surgical intervention:

  • Radical debridement of pressure sore
  • Bone marrow harvest from the iliac crest
  • Isolation of hematopoietic stem cells, aiming to gain > 1 mio. CD 34+ cells per patient under GMP conditions

3. Stem cell therapy (after 2 days)

  • Injection of stem cells in suspension (50'000 CD 34+ cells in 100 microliter saline per cm2 of wound surface) on one half of the total wound surface and cell-free saline on the other half as a control

4. Second surgical intervention (after 3-4 weeks):

  • Complete excision of the wound
  • Closure of the defect by fasciocutaneous flap

5. Evaluation of wound healing:

  • Clinical
  • 3D laser imaging
  • Histology
  • Growth factor assay

研究设计

研究类型
Interventional
分配方式
Na
干预模型
Single Group
主要目的
Basic Science
盲法
Single (Participant)

入排标准

年龄范围
18 Years 至 50 Years(Adult)
性别
All
接受健康志愿者

入选标准

  • Para- or tetraplegic
  • Sacral pressure sores
  • Grade III-IV according to classification of Daniel and Seiler

排除标准

  • Diabetes mellitus
  • Peripheral vascular disease
  • Coronary artery disease
  • Steroids and other immunosuppressive drugs
  • Systemic autoimmune or rheumatoid diseases
  • Hepatitis B/C

结局指标

主要结局

feasibility, safety, efficacy

时间窗: 1 yr

次要结局

未报告次要终点

研究者

发起方
University Hospital, Basel, Switzerland
申办方类型
Other

研究点 (2)

Loading locations...

相似试验